Trevena Inc (TRVN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

955 CHESTERBROOK BOULEVARD CHESTERBROOK, PA 19087

Trevena, Inc. develops pharmaceutical products. The company offers discovery and development of agents targeting G-protein coupled receptors and therapies and drugs that treat acute heart failure, acute chronic pain, and depression. Trevena serves customers throughout the United States.

Data as of 2020-10-17
Market Cap450.907 Million Shares Outstanding153.37 Million Avg 30-day Volume7.508 Million
P/E Ratio Dividend Yield EPS-0.28
Price/Sales14545.4 Price cash flow ratio Price free cash flow ratio-24.5
Book Value0.36 Price to Tangible Book8.12 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.142173
BETA2.73037 52-week High/Low3.68 / 0.46 Stddev0.310985
View SEC Filings from TRVN instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 64 52 23.08% 12 (0.78%) 10 (0.64%) 20.0%
13F shares: 19.625 Million 17.286 Million 13.53% 5.531 Million 3.99 Million 38.61%
% Ownership 18.3099 17.6637 3.66% 5.1602 4.0772 26.56%
New Positions: 18 8 125.0% 3 2 50.0%
Increased Positions 19 13 46.15% 3 2 50.0%
Closed Positions 4 7 -42.86% 1 3 -66.67%
Reduced Positions 6 6 0.0% 2 1 100.0%
Total Calls 333.846 Thousand 39.814 Thousand 738.51% 23.3 Thousand
Total Puts 26.819 Thousand 0 10.8 Thousand
PUT/CALL Ratio 0.08 0.0 0.46
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TRVN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TRVN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

YODER ROBERT T SR. VP, CHIEF BUSINESS OFFICER

  • Officer
0 2020-10-02 3

SHIN BARRY CHIEF FINANCIAL OFFICER

  • Officer
445,461 2020-06-25 2

MCHUGH JULIE

  • Director
0 2020-05-13 1

YANNI BARBARA

  • Director
0 2020-05-13 1

GOWEN MAXINE

  • Director
0 2020-05-13 1

DOUGHERTY MICHAEL R

  • Director
0 2020-05-13 1

MOULDER LEON O JR

  • Director
0 2020-05-13 1

PHILLIPS ANNE M.

  • Director
0 2020-05-13 1

NUNN JASON RALEIGH

  • Director
0 2020-05-13 1

BRAUNSTEIN SCOTT

  • Director
0 2020-05-13 1

APPLEBAUM SCOTT CLCO; SVP REGULATORY AFFAIRS

  • Officer
0 2020-02-10 2

BOURDOW CARRIE L. PRESIDENT AND CEO

  • Officer
  • Director
925,894 2019-12-12 2

DEMITRACK MARK SR. VP & CHIEF MEDICAL OFFICER

  • Officer
320,038 2019-12-12 2

HAMILL JOHN P. VP FIN,PRINC FIN&ACCT OFFICER

  • Officer
82,234 2019-05-31 0

KOPPEL ADAM

  • Director
0 2018-05-16 0

HABIB YACOUB SVP, BUS DEV & CORP PLANNING

  • Officer
0 2018-03-22 0

CUCA ROBERTO SR. VP AND CFO

  • Officer
0 2018-02-28 0

LIMONGELLI JOHN M SR. VP,GENERAL COUNSEL & CAO

  • Officer
0 2018-02-28 0

GEOGHEGAN DAVID SR. VP, OPERATIONS

  • Officer
0 2018-02-28 0

VIOLIN JONATHAN SVP-SCIENTIFIC AFFAIRS & IR

  • Officer
0 2018-02-28 0

LARK MICHAEL W. SR. VP, RESEARCH & CSO

  • Officer
0 2017-08-28 0

SOERGEL DAVID SR. VP,CLINICAL DEV. & CMO

  • Officer
0 2017-03-02 0

NADER FRANCOIS

  • Director
0 2015-05-20 0

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

NEA PARTNERS 12, LIMITED PARTNERSHIP

NEA 12 GP, LLC

BARRETT M JAMES

BARRIS PETER J

BASKETT FOREST

DRANT RYAN D

KERINS PATRICK J

KOLLURI KRISHNA KITTU

SANDELL SCOTT D

  • 10% Owner
4,811,691 2014-12-10 0

ALTA PARTNERS VIII, L.P.

ALTA PARTNERS MANAGEMENT VIII, LLC

CHAMPSI FARAH

JANNEY DANIEL

NOHRA GUY P

  • Director
  • 10% Owner
4,390,262 2014-12-10 0

DEEGAN ROSAMOND SR VP, BUS DEV & OPERATIONS

  • Officer
31,105 2014-09-29 0

POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

POLARIS VENTURE PARTNERS V, L.P.

POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

MCGUIRE TERRANCE

FLINT JONATHAN A

  • 10% Owner
3,769,280 2014-08-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

YODER ROBERT T - Officer SR. VP, CHIEF BUSINESS OFFICER

2020-10-08 16:19:11 -0400 2020-10-02 A 59,000 a 59,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments